All Oncology News

Simon Rule, MD, PhD, discusses pooled findings examining ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Katherine D. Crew, MD, discusses the results of HER2CLIMB and DESTINY-Breast01, as well as other impactful data in HER2-positive breast cancer that emerged from the 2019 San Antonio Breast Cancer Symposium.

The FDA has extended the Prescription Drug User Fee Act deadline for a new drug application for avapritinib as a treatment for adult patients with fourth-line gastrointestinal stromal tumor.

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Rita Nanda, MD, discusses ongoing advances with immunotherapy in triple-negative breast cancer, as well as develops in the HER2-negative breast cancer paradigm.

Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.

Eileen Connolly, MD, PhD, reflects on novel radiation techniques, as well as ongoing research and challenges with radiation therapy in breast cancer.

Antonio González-Martín, MD, discusses the design and findings of the PRIMA trial in advanced ovarian cancer.

The Association of Community Cancer Centers is pleased to announce that its Multidisciplinary Chronic Lymphocytic Leukemia Care education project is conducting a series of quality improvement workshops to promote the optimal care and management of patients diagnosed with chronic lymphocytic leukemia.

Katherine D. Crew, MD, discusses the updated results of the KATHERINE trial, as well as other data regarding the adjuvant treatment paradigm in early-stage HER2-positive breast cancer.

Thomas J. Polascik, MD, discusses the growing relevance of genetic testing for men with prostate cancer and those at a high risk of developing the disease.

Adam M. Brufsky, MD, PhD, FACP, discusses the emergence of biosimilars in oncology and how he anticipates they will change the paradigm.

Roy S. Herbst, MD, PhD, discusses research regarding immunotherapy and accompanying biomarkers in non–small cell lung cancer.

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Melissa K. Accordino, MD, MS, discusses the treatment options for patients with hormone receptor-positive, HER2-negative breast cancer.

James M. Reuben, PhD, MBA, discusses his research on using liquid biopsies to identify predictive biomarkers for immunotherapy in patients with metastatic breast cancer.

Dawn L. Hershman, MD, MS, discusses current treatment considerations in premenopausal women with early-stage, hormone receptor-positive breast cancer.

Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for the rituximab biosimilar PF-05280586 for the treatment of patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

The European Medicines Agency has validated a Marketing Authorization Application for belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed monoclonal antibody.

The addition of dinutuximab injection to irinotecan did not improve overall survival compared with irinotecan or topotecan alone in patients with relapsed/refractory small cell lung cancer, missing the primary endpoint of the phase II/III DISTINCT trial.

Kevin Kalinsky, MD, MS, highlights recent developments in triple-negative breast cancer, including the potential role of immunotherapy in the neoadjuvant setting.

Farrukh Awan, MD, discusses the introduction of acalabrutinib into chronic lymphocytic leukemia as well as other paradigm-shifting advances with BTK inhibitors, novel combinations, and emerging agents.

Bristol-Myers Squibb has withdrawn its application in the European Union for the frontline combination of nivolumab and ipilimumab as a treatment for patients with advanced non–small cell lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease.

Praveen Ramakrishnan, MD, spotlights some of the exciting data recently presented across the spectrum of non-Hodgkin lymphoma treatment.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Douglas W. Blayney, MD, discusses phase II results of the combination of pegfilgrastim and plinabulin, as well as the importance of controlling chemotherapy-induced neutropenia for patients.

The European Medicines Agency has validated a Marketing Authorization Application for tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, who have received ≥2 prior anti-HER2 treatment regimens.

The FDA has granted a breakthrough therapy designation to the combination of APR-246 and azacitidine for the treatment of patients with myelodysplastic syndromes with a susceptible TP53 mutation.